Immunocore (NASDAQ:IMCR) Cut to Neutral at Mizuho

Mizuho cut shares of Immunocore (NASDAQ:IMCR) from an outperform rating to a neutral rating in a report issued on Monday, Marketbeat.com reports. They currently have $38.00 target price on the stock, down from their prior target price of $72.00.

Other equities research analysts also recently issued research reports about the company. HC Wainwright reaffirmed a “buy” rating and issued a $100.00 target price on shares of Immunocore in a research report on Thursday, October 24th. UBS Group began coverage on shares of Immunocore in a research report on Thursday, October 24th. They set a “sell” rating and a $24.00 price target on the stock. Morgan Stanley lowered their target price on shares of Immunocore from $80.00 to $74.00 and set an “overweight” rating for the company in a research note on Friday, October 11th. Needham & Company LLC cut their price target on Immunocore from $78.00 to $71.00 and set a “buy” rating on the stock in a report on Thursday, November 7th. Finally, Barclays decreased their target price on shares of Immunocore from $92.00 to $66.00 and set an “overweight” rating for the company in a research report on Friday, August 9th. One analyst has rated the stock with a sell rating, three have issued a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Immunocore currently has a consensus rating of “Moderate Buy” and an average price target of $69.18.

Immunocore Stock Up 1.2 %

IMCR opened at $34.17 on Monday. Immunocore has a 52 week low of $29.72 and a 52 week high of $76.98. The company has a quick ratio of 3.76, a current ratio of 3.78 and a debt-to-equity ratio of 1.03. The business has a 50 day moving average price of $32.56 and a two-hundred day moving average price of $38.92.

Immunocore (NASDAQ:IMCR) last announced its quarterly earnings results on Wednesday, November 6th. The company reported $0.17 EPS for the quarter, topping the consensus estimate of ($0.33) by $0.50. Immunocore had a negative return on equity of 12.84% and a negative net margin of 15.87%. The business had revenue of $80.25 million for the quarter, compared to analyst estimates of $78.94 million. During the same quarter in the previous year, the company earned ($0.59) EPS. The company’s quarterly revenue was up 23.7% on a year-over-year basis. On average, equities research analysts predict that Immunocore will post -0.96 EPS for the current fiscal year.

Institutional Trading of Immunocore

A number of institutional investors and hedge funds have recently modified their holdings of IMCR. Exchange Traded Concepts LLC boosted its stake in Immunocore by 40.4% during the third quarter. Exchange Traded Concepts LLC now owns 5,075 shares of the company’s stock worth $158,000 after buying an additional 1,461 shares in the last quarter. Connective Portfolio Management LLC acquired a new stake in shares of Immunocore during the 3rd quarter valued at about $218,000. China Universal Asset Management Co. Ltd. increased its stake in Immunocore by 69.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 7,433 shares of the company’s stock valued at $231,000 after acquiring an additional 3,053 shares during the period. DNB Asset Management AS raised its position in Immunocore by 35.0% in the second quarter. DNB Asset Management AS now owns 7,211 shares of the company’s stock worth $244,000 after purchasing an additional 1,868 shares in the last quarter. Finally, XTX Topco Ltd bought a new position in Immunocore during the second quarter worth about $303,000. 84.50% of the stock is currently owned by institutional investors.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.